Tetra Bio-Pharma’s PPP004 receives orphan drug status

Tetra Bio-Pharma’s PPP004 receives orphan drug status

Tetra Bio-Pharma’s PPP004, a cannabinoid-derived cream, has been granted Orphan Drug Designation by the European Medicines Agency (EMA).

EMA Orphan Drug Designation supports the development of investigational products that are intended to treat rare diseases affecting fewer than 5 in 10,000 people.

Read the press release from Tetra Bio-Pharma.



Cure EB
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.